Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 2/20 | 0.51 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 10/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.42 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | STAT3 | P40763 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18325821 | 0.91 | PAK4 (0.52) | PAK4GABRA5HRH3NAMPTPAK1 | |
| SCHEMBL18325792 | 0.88 | HRH3 (0.47) | PAK4HRH3STAT3 | |
| SCHEMBL18325770 | 0.88 | HRH3 (0.56) | GABRA5HRH3HPGD | |
| SCHEMBL16345167 | 0.88 | PAK4 (0.57) | PAK4GABRA5HRH3NAMPTPAK1 | |
| SCHEMBL18325865 | 0.87 | PAK4 (0.46) | PAK4GABRA5HRH3NAMPTPAK1 | |
| SCHEMBL18325949 | 0.87 | PAK4 (0.41) | PAK4GABRA5NAMPTPAK1LRRK2 | |
| SCHEMBL18325828 | 0.86 | PAK4 (0.67) | PAK4GABRA5HRH3NAMPTPAK1 | |
| SCHEMBL18325818 | 0.86 | PAK4 (0.51) | PAK4GABRA5HRH3NAMPTPAK1 | |
| SCHEMBL18325816 | 0.86 | PAK4 (0.52) | PAK4GABRA5HRH3NAMPTPAK1 | |
| SCHEMBL18325835 | 0.86 | PAK4 (0.57) | PAK4GABRA5HRH3NAMPTPAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856241-B2 | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | Karyopharm Therapeutics Inc. (US) | 2018-01-02 | — | — | US | disclosed |
| US-20160368904-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | Karyopharm Therapeutics Inc. | 2016-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368904-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | BCL6, MALT1, BTK | PAK4 2007/4885GABRA5 55/4885HRH3 4677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.